Trial Profile
Reductions in glycaemia and weight with once-weekly dosing of LY2189265, a long-acting glucagon-like peptide 1 (GLP-1) analogue in patients with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Sep 2009 Results have been presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Sep 2009 New trial record